Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society.

Duru N, Candas D, Jiang G, Li JJ.

J Cancer Res Clin Oncol. 2014 Jan;140(1):1-14. doi: 10.1007/s00432-013-1494-1. Epub 2013 Aug 30. Review.

2.

NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance.

Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, Dynlacht JR, Li JJ.

Radiat Res. 2009 Jan;171(1):9-21. doi: 10.1667/RR1472.1.

3.

Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.

Pommier SJ, Quan GG, Christante D, Muller P, Newell AE, Olson SB, Diggs B, Muldoon L, Neuwelt E, Pommier RF.

Ann Surg Oncol. 2010 Feb;17(2):613-23. doi: 10.1245/s10434-009-0730-z. Epub 2009 Oct 17.

PMID:
19838757
4.

Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation.

Glinka Y, Mohammed N, Subramaniam V, Jothy S, Prud'homme GJ.

Biochem Biophys Res Commun. 2012 Sep 7;425(4):775-80. doi: 10.1016/j.bbrc.2012.07.151. Epub 2012 Aug 2.

PMID:
22885184
5.

NF-κB, stem cells and breast cancer: the links get stronger.

Shostak K, Chariot A.

Breast Cancer Res. 2011 Jul 26;13(4):214. doi: 10.1186/bcr2886. Review.

6.

Targeted therapies of metastatic breast cancer: relationships with cancer stem cells.

Ferrari P, Nicolini A, Carpi A.

Biomed Pharmacother. 2013 Jul;67(6):543-55. doi: 10.1016/j.biopha.2013.03.006. Epub 2013 Apr 3. Review.

PMID:
23643355
7.

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.

Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E, Jones FE.

Mol Cancer Ther. 2009 Aug;8(8):2152-62. doi: 10.1158/1535-7163.MCT-09-0295. Epub 2009 Aug 11.

8.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.

Int J Oncol. 2010 Sep;37(3):669-78.

PMID:
20664936
9.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.

Breast Cancer Res. 2013;15(5):R101.

10.

V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.

von Schwarzenberg K, Lajtos T, Simon L, Müller R, Vereb G, Vollmar AM.

Mol Oncol. 2014 Feb;8(1):9-19. doi: 10.1016/j.molonc.2013.08.011. Epub 2013 Sep 5.

11.

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.

Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, Brandt BH, Dittmar T.

J Pathol. 2012 Jun;227(2):234-44. doi: 10.1002/path.3991. Epub 2012 Mar 21. Erratum in: J Pathol. 2013 May;230(1):e1.

PMID:
22262199
12.

Epithelial-mesenchymal transition, cancer stem cells and treatment resistance.

Dave B, Mittal V, Tan NM, Chang JC.

Breast Cancer Res. 2012 Jan 19;14(1):202. Review.

13.

ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri L, Harel-Bellan A, Chaffanet M, Viens P, Birnbaum D.

Cancer Res. 2013 Dec 15;73(24):7290-300. doi: 10.1158/0008-5472.CAN-12-4704. Epub 2013 Oct 18.

15.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

PMID:
20087739
16.

Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation.

Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C, Chen XF, Park S, Ju J, Chen EI.

Breast Cancer Res. 2010;12(6):R94. doi: 10.1186/bcr2773. Epub 2010 Nov 10.

17.

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.

Cancer Res. 2009 Oct 15;69(20):8058-66. doi: 10.1158/0008-5472.CAN-09-0834. Epub 2009 Oct 13.

18.

Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?

Ito Y, Iwase T, Hatake K.

Breast Cancer. 2012 Jul;19(3):206-11. doi: 10.1007/s12282-011-0266-5. Epub 2011 Apr 28. Review.

PMID:
21526426
19.

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Mar 1;68(5):1471-7. doi: 10.1158/0008-5472.CAN-07-5962.

20.

Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.

Huang Y, Fu P, Fan W.

Curr Drug Targets. 2013 Jul;14(8):889-98. Review.

PMID:
23531110

Supplemental Content

Support Center